Insulet Corporation has officially outlined its roadmap for the commercialization of its next-generation insulin delivery technology, aiming for a 2028 market entry for its fully closed-loop system. During a recent earnings call and subsequent data releases, the company confirmed plans to initiate a pivotal clinical trial this year, which will serve as the foundation for a 510(k) submission to the U.S. Food and Drug Administration (FDA) in 2027. This development marks a significant milestone in the evolution of diabetes management, as the industry moves toward autonomous insulin delivery that removes the "mental load" of the disease from the patient.
The transition from hybrid closed-loop systems to fully closed-loop systems represents the most anticipated shift in the MedTech diabetes sector. Current hybrid systems, including Insulet’s own Omnipod 5, require users to manually input carbohydrate counts for meals and confirm bolus dosages. A fully closed-loop system, by contrast, is designed to function autonomously, utilizing advanced algorithms to adjust insulin delivery in real-time based on continuous glucose monitor (CGM) data without requiring user intervention for meals or corrective doses.
Defining the Fully Closed-Loop Standard
The conceptual framework for this new technology was detailed by Insulet CEO Ashley McEvoy during the company’s fourth-quarter earnings call. McEvoy defined a "fully closed-loop" system as one that adapts to the physiological needs of the patient without any manual input. This eliminates the need for clinicians to define initial basal settings or for patients to perform the often-inaccurate task of carbohydrate counting.
The goal of this technology is to transform insulin therapy from a proactive, labor-intensive process into a passive, background utility. For decades, patients have been burdened with the mathematical complexity of calculating insulin-to-carb ratios and correction factors. By automating these processes, Insulet aims to improve both clinical outcomes and the quality of life for millions of individuals living with insulin-dependent diabetes.
Clinical Trial Data and Algorithmic Evolution
The push toward a 2028 launch is supported by robust clinical data. Last year, Insulet published early-stage clinical findings on an initial version of its fully closed-loop algorithm. The feedback from those early trials led to specific refinements intended to simplify the user interface and improve the algorithm’s responsiveness to rapid glucose fluctuations, particularly during and after meals.
In the most recent clinical trial results reported this week, Insulet tested multiple iterations of the algorithm to identify the most effective version for a pivotal study. The final version of the algorithm, which operated without manual bolus insulin, demonstrated a mean "time in range" (TIR) of 68%. This represents a 24% improvement over standard multiple daily injection (MDI) therapy, which remains the most common form of insulin delivery globally.
Furthermore, the safety profile of the system was a highlight of the data. The median time spent below the target glucose range—indicating hypoglycemia—was just 0.14%. This is well below the American Diabetes Association (ADA) recommendation, which suggests that patients should spend less than 4% of their time in a hypoglycemic state. Importantly, no participants in the study experienced severe hypoglycemia or diabetic ketoacidosis (DKA), the two most dangerous acute complications associated with insulin therapy.
Patient engagement during the trial also provided a qualitative signal of the technology’s potential. More than 90% of the participants elected to join an ongoing extension phase of the study. According to Insulet, this high retention rate reflects a strong positive experience and a high level of trust in the system’s ability to manage glucose levels without constant supervision.
The Competitive Landscape: Tandem and Medtronic
Insulet is not alone in its pursuit of the fully closed-loop "holy grail." The race for market dominance in the insulin pump space is currently a three-way contest between Insulet, Tandem Diabetes Care, and Medtronic.
Tandem Diabetes Care is following a remarkably similar trajectory. Tandem CEO John Sheridan recently informed investors that his company also plans to launch a pivotal trial for its autonomous algorithm within the current calendar year. Tandem expects to file for FDA clearance in 2027, positioning itself as a direct competitor to Insulet’s 2028 launch window. Tandem’s strategy focuses on integrating its technology with a variety of CGM sensors, leveraging its "open ecosystem" approach.
Meanwhile, Medtronic has taken aggressive steps to reclaim its historical leadership in the pump market. The company recently disclosed the commencement of a pivotal trial for its "Vivera" fully closed-loop algorithm. This announcement coincided with a major corporate restructuring in which Medtronic spun off its diabetes division into an independent entity via the MiniMed initial public offering (IPO). The MiniMed Vivera algorithm has already shown impressive preliminary results; in a feasibility study, the system achieved a mean TIR of 73.8% without any manual user input.
Targeting the Type 2 Diabetes Market
While much of the historical focus of insulin pump technology has been on the Type 1 diabetes population, Insulet is increasingly looking toward the Type 2 market as a primary driver of future growth. CEO Ashley McEvoy highlighted a stark reality during the earnings call: of the 5.5 million people in the United States with Type 2 diabetes who require insulin, only 25% are currently achieving their recommended glucose targets.
The complexity of managing Type 2 diabetes with insulin often leads to "clinical inertia," where both patients and providers hesitate to intensify therapy due to the risk of hypoglycemia and the burden of management. A fully closed-loop system could lower the barrier to entry for these patients, providing a "set it and forget it" solution that brings their glucose levels into a healthy range without requiring specialized endocrinology knowledge.
Market analysts suggest that the Type 2 segment represents a multi-billion-dollar opportunity for Insulet, especially as the Omnipod’s tubeless, wearable form factor is often more appealing to Type 2 patients than traditional tethered pumps.
Chronology of Development and Regulatory Pathway
The path to 2028 is marked by several critical regulatory and developmental milestones:
- 2023: Publication of early-stage clinical data and initial algorithm testing.
- 2024: Finalization of the algorithm and the start of the pivotal clinical trial. This trial will involve a larger, more diverse patient population to satisfy FDA requirements for safety and efficacy across various demographics.
- 2025–2026: Completion of the pivotal trial and data analysis. This period will also involve manufacturing scaling and software finalization.
- 2027: Submission of the 510(k) premarket notification to the FDA. The 510(k) pathway is used for medical devices that are "substantially equivalent" to a legally marketed device, though the novel nature of the fully closed-loop algorithm may require extensive clinical backing.
- 2028: Expected FDA clearance and commercial launch in the United States, followed by international rollouts.
Industry Implications and Future Outlook
The move toward fully autonomous insulin delivery is expected to have far-reaching implications for the healthcare system. By improving Time in Range and reducing the incidence of severe hypoglycemia, these systems could significantly lower the long-term costs associated with diabetes complications, such as kidney disease, retinopathy, and cardiovascular events.
However, challenges remain. The "fully closed-loop" designation requires a level of algorithmic reliability that can account for variables like high-fat meals, intense exercise, and illness—all of which affect insulin sensitivity in unpredictable ways. Furthermore, the success of these systems is heavily dependent on the accuracy and lag-time of CGM sensors. As CGM technology continues to improve, the "brain" of the insulin pump (the algorithm) will have better data to work with.
Insulet’s 2028 target is ambitious but reflects the current pace of innovation in the MedTech sector. As the company moves into its pivotal trial phase, the focus will remain on proving that its algorithm can handle the complexities of daily life better than the human mind can. If successful, the launch will not just be a win for Insulet’s shareholders, but a transformative moment for millions of patients who will finally be able to live their lives without the constant shadow of glucose monitoring.